HS-001
undisclosedTreat severe heart failure by regenerating heart muscle with transplanted cardiomyocytes.
Allogeneic iPS cell-derived cardiomyocyte spheroids delivered into the myocardium. LAPiS evaluates transplantation in patients with underlying ischemic heart disease; EMERALD evaluates endocardial delivery in patients with reduced ejection fraction.
Clinical evaluation documented in the LAPiS and EMERALD study records, with safety and efficacy assessed over 26 weeks after transplantation. Trial phases are not supplied.
